Restricted accessResearch articleFirst published online 2020-11
Genomic and Clinical Characterization of IMP-1-Producing Multidrug-Resistant Acinetobacter bereziniae Isolates from Bloodstream Infections in a Brazilian Tertiary Hospital
Acinetobacter baumannii is the main species of the Acinetobacter genus; however, non-baumannii Acinetobacter (NBA) species causing infections have been described for the past years, as well as antimicrobial resistance. In this study, we describe the occurrence of two multidrug-resistant (MDR) IMP-1-producing Acinetobacter bereziniae isolates recovered from bloodstream infections in different patients but in the same intensive care unit among 134 carbapenem-resistant Acinetobacter screened. Antimicrobial susceptibility testing revealed resistance to carbapenems, extended spectrum, and antipseudomonad cephalosporins, amikacin, and trimethoprim-sulfamethoxazole. Both A. bereziniae isolates shared the same ApaI-pulsed-field gel electrophoresis (PFGE) pattern. Whole-genome sequencing of both isolates revealed that blaIMP-1 was embedded into an In86 Class I integron carrying also sul1, aac(6′)-31, and aadA genes. A new sequence type (ST1309 Pasteur) was deposited. The virulence genes lpxC and ompA, seen in A. baumannii, were detected in the A. bereziniae strains. Recognition of A. bereziniae causing invasive MDR infection underscores the role of NBA species as human pathogens especially in at-risk patients.
Get full access to this article
View all access options for this article.
References
1.
MaragakisL.L., and PerlT.M.. 2008. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin. Infect. Dis. 46:1254–1263.
2.
PelegA.Y., and PatersonD.L.. 2006. Multidrug-resistant Acinetobacter: a threat to the antibiotic era. Intern. Med. J. 36:479–482.
3.
PelegA.Y., SeifertH., and PatersonD.L.. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538–582.
4.
KramerA., SchwebkeI., and KampfG.. 2006. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect. Dis. 6:130.
5.
Al AtrouniA., Joly-GuillouM.-L, HamzeM., and KempfM.. 2016. Reservoirs of non-baumannii Acinetobacter species. Front. Microbiol. 7:49.
6.
CayôR., StrelingA.P, NodariC.S, MatosA.P, de Paula LuzA., DijkshoornL., PignatariA.C.C, and GalesA.C.. 2018. Occurrence of IMP-1 in non-baumannii Acinetobacter clinical isolates from Brazil. J. Med. Microbiol. 67:628–630.
7.
BonninR.A., Ocampo-SosaA.A, PoirelL., Guet-RevilletH., and NordmannP.. 2012. Biochemical and genetic characterization of carbapenem-hydrolyzing β-lactamase OXA-229 from Acinetobacter bereziniae. Antimicrob. Agents Chemother. 56:3923–3927.
8.
ParkY.K., JungS.-I, ParkK.-H, KimS.H, and KoK.S.. 2012. Characteristics of carbapenem-resistant Acinetobacter spp. other than Acinetobacter baumannii in South Korea. Int. J. Antimicrob. Agents, 39:81–85.
9.
SungJ.Y., KooS.H, KimS., and KwonK.C.. 2014. Epidemiological characterizations of class 1 integrons from multidrug-resistant Acinetobacter isolates in Daejeon, Korea. Ann. Lab. Med. 34:293.
10.
WatanabeM., IyobeS., InoueM., and MitsuhashiS.. 1991. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 35:147–151.
11.
MatsumuraY., PeiranoG., MotylM.R, AdamsM.D, ChenL., KreiswirthB., DeVinneyR., and PitoutJ.D.. 2017. Global molecular epidemiology of IMP-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 61:e02729-16.
12.
KazmierczakK.M., RabineS., HackelM., McLaughlinR.E, BiedenbachD.J, BouchillonS.K, SahmD.F, and BradfordP.A.. 2016. Multiyear, multinational survey of the incidence and global distribution of metallo-β-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 60:1067–1078.
13.
MojicaM.F., BonomoR.A, and FastW.. 2016. B1-Metallo-β-Lactamases: where do we stand? Curr. Drug Targets, 17:1029–1050.
14.
KouyamaY., HaradaS., IshiiY., SagaT., YoshizumiA., TatedaK., and YamaguchiK.. 2012. Molecular characterization of carbapenem-non-susceptible Acinetobacter spp. in Japan: predominance of multidrug-resistant Acinetobacter baumannii clonal complex 92 and IMP-type metallo-β-lactamase-producing non-baumannii Acinetobacter species. J. Infect. Chemother. 18:522–528.
15.
PaganoM., MartinsA.F, and BarthA.L.. 2016. Mobile genetic elements related to carbapenem resistance in Acinetobacter baumannii. Braz. J. Microbiol. 47:785–792.
16.
BonomoR.A., and SzaboD.. 2006. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis. 43 Suppl, 2:S49–S56.
17.
ChatterjeeS., DattaS., RoyS., RamananL., SahaA., ViswanathanR., SomT., and BasuS.. 2016. Carbapenem resistance in Acinetobacter baumannii. and other Acinetobacter spp. causing neonatal sepsis: focus on NDM-1 and its linkage to ISAba125. Front. Microbiol. 7:, 1126.
18.
LuP.-L., HuangL.-Y, LianS.-T, ChangK., LinC.-L, HwangI.-J, ChiangW.G, ChenY.H, LinS.F, and SiuL.K.. 2008. How carbapenem-resistant Acinetobacter spp. established in a newly constructed hospital. Int. J. Antimicrob. Agents, 31:463–466.
19.
ZhangR., HuY.-Y, YangX.-F, GuD.-X, ZhouH.-W, HuQ.-F, ZhaoK., YuS.F, and ChenG.X.. 2014. Emergence of NDM-producing non-baumannii Acinetobacter spp. isolated from China. Eur. J. Clin. Microbiol. Infect. Dis. 33:853–860.
20.
EspinalP., RocaI., and VilaJ.. 2011. Clinical impact and molecular basis of antimicrobial resistance in non-baumannii Acinetobacter. Future Microbiol. 6:495–511.
21.
KamolvitW., HigginsP.G, PatersonD.L, and SeifertH.. 2014. Multiplex PCR to detect the genes encoding naturally occurring oxacillinases in Acinetobacter spp. J. Antimicrob. Chemother. 69:959–963.
22.
TurtonJ.F., ShahJ., OzongwuC., and PikeR.. 2010. Incidence of Acinetobacter species other than A. baumannii among clinical isolates of Acinetobacter: evidence for emerging species. J. Clin. Microbiol. 48:1445–1449.
23.
LeeK., KimC.K, HongS.G, ChoiJ., SongS., KohE., YongD., JeongS.H, YumJ.H, DocquierJ.D, RossoliniG.M, and ChongY.. 2010. Characteristics of clinical isolates of Acinetobacter genomospecies 10 carrying two different metallo-β-lactamases. Int. J. Antimicrob. Agents, 36:259–263.
24.
GrossoF., SilvaL., SousaC., RamosH., QuinteiraS., and PeixeL.. 2015. Extending the reservoir of blaIMP-5: the emerging pathogen Acinetobacter bereziniae. Future Microbiol. 10:1609–1613.
25.
WoodfordN., EllingtonM.J, CoelhoJ.M, TurtonJ.F, WardM.E, BrownS., AmyesS.G, and LivermoreD.M.. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents, 27:351–353.
26.
HigginsP.G., LehmannM., and SeifertH.. 2010. Inclusion of OXA-143 primers in a multiplex polymerase chain reaction (PCR) for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents, 35:305.
27.
PoirelL., WalshT.R, CuvillierV., and NordmannP.. 2011. Multiplex PCR for detection of acquired carbapenemase genes. Diagn. Microbiol. Infect. Dis. 70:119–123.
28.
La ScolaB., GundiV.A, KhamisA., and RaoultD.. 2006. Sequencing of the rpoB gene and flanking spacers for molecular identification of Acinetobacter species. J. Clin. Microbiol. 44:827–832.
29.
ChangH.C., WeiY.F, DijkshoornL., VaneechoutteM., TangC.T, and ChangT.C.. 2005. Species-level identification of isolates of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex by sequence analysis of the 16S-23S rRNA gene spacer region. J. Clin. Microbiol. 43:1632–1639.
30.
SeifertH., DolzaniL., BressanR., van der ReijdenT., van StrijenB., StefanikD., HeersmaH., and DijkshoornL.. 2005. Standardization and interlaboratory reproducibility assessment of pulsed-field gel electrophoresis-generated fingerprints of Acinetobacter baumannii. J. Clin. Microbiol. 43:4328–4335.
31.
ChewK.L., LaM.-V, LinR.T.P, and TeoJ.W.P. 2017. Colistin and polymyxin B susceptibility testing for carbapenem-resistant and mcr-positive Enterobacteriaceae: comparison of Sensititre, MicroScan, Vitek 2, and Etest with broth microdilution. J. Clin. Microbiol. 55:2609–2616.
MagiorakosA.P., SrinivasanA., CareyR.B, CarmeliY., FalagasM.E, GiskeC.G, HarbarthS., HindlerJ.F, KahlmeterG., Olsson-LiljequistB., PatersonD.L, RiceL.B, StellingJ., StruelensM.J, VatopoulosA., WeberJ.T, and MonnetD.L.. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18:268–281.
34.
SullivanM.J., PettyN.K, and BeatsonS.A.. 2011. Easyfig: a genome comparison visualizer. Bioinformatics, 27:1009–1010.
35.
KaasR.S., LeekitcharoenphonP., AarestrupF.M, and LundO.. 2014. Solving the problem of comparing whole bacterial genomes across different sequencing platforms. PLoS One, 9:e104984.
36.
ChagasT.P.G., Carvalho-AssefA.P.D, Martins AiresC.A, BertociniR., and AsensiM.D.. 2015. Detection of an NDM-1-producing Acinetobacter bereziniae strain in Brazil. J. Glob. Antimicrob. Resist. 3:147–148.
37.
MendesR.E., CastanheiraM., TolemanM.A, SaderH.S, JonesR.N, and WalshT.R.. 2007. Characterization of an integron carrying blaIMP-1 and a new aminoglycoside resistance gene, aac(6’)-31, and its dissemination among genetically unrelated clinical isolates in a Brazilian hospital. Antimicrob. Agents Chemother. 51:2611–2614.
38.
BrovedanM., MarchiaroP.M, Morán-BarrioJ., RevaleS., CameranesiM., BrambillaL., VialeA.M, and LimanskyA.S.. 2016. Draft genome sequence of Acinetobacter bereziniae HPC229, a carbapenem-resistant clinical strain from Argentina harboring blaNDM-1. Genome Announc. 4:e00117-16.
39.
BrovedanM., MarchiaroP.M, Morán-BarrioJ., CameranesiM., CeraG., RinaudoM., VialeA.M, and LimanskyA.S.. 2015. Complete sequence of a bla(NDM-1)-harboring plasmid in an Acinetobacter bereziniae clinical strain isolated in Argentina. Antimicrob. Agents Chemother. 59:6667–6669.
40.
BonninR.A., PoirelL., LickerM., and NordmannP.. 2011. Genetic diversity of carbapenem-hydrolysing β-lactamases in Acinetobacter baumannii from Romanian hospitals. Clin. Microbiol. Infect. 17:1524–1528.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
